Glenmark Pharmaceuticals receives ANDA approval for Telmisartan and Hydrochlorothiazide Tablets USP, 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg
Deepthi | Myequity news | Date : 05-03-2019 10:40:00 IST
Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Telmisartan and Hydrochlorothiazide Tablets USP, 40 mg/12.5 mg, 80 mg/12.5 mg, and 80 mg/25 mg, a generic version of Micardis®1 HCT Tablets, of Boehringer Ingelheim Pharmaceuticals, Inc.
According to IQVIATM sales data for the 12 month period ending January 2019, the Micardis® HCT Tablets market2 achieved annual sales of approximately $40.6 million.
About Glenmark Pharmaceuticals
Glenmark Pharmaceuticals Ltd. (GPL) is a research‐driven, global, integrated pharmaceutical organization. Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.